Galectin Therapeutics (GALT) sinks 39% as trading resumes

September 27, 2016 4:47 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Galectin Therapeutics (NASDAQ: GALT) sinks 39% as trading resumes after a recent trial failed.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Momentum Movers, Trader Talk, Trading Halts

Add Your Comment